AstraZeneca’s COVID-19 vaccine is 74 percent effective in preventing symptomatic illness, according to data from its U.S. clinical trial published in the New England Journal of Medicine on Wednesday. The phase 3 trial involved more than 32,000 participants in the United States, Peru, and Chile, who either received two doses of the COVID-19 vaccine or

Leave a Reply